Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response

Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response

Abstract The landscape of current cancer immunotherapy is dominated by antibodies targeting PD-1/PD-L1 and CTLA-4 that have transformed cancer therapy, yet their efficacy is limited by primary and acquired resistance. The blockade of additional immune checkpoints, especially TIGIT and LAG-3, has bee...

Full description

Bibliographic Details
Main Authors: Riyao Yang, Su Huang, Cai Huang, Nathan S. Fay, Yanan Wang, Saroja Putrevu, Kimberly Wright, Mohd Saif Zaman, Wenyan Cai, Betty Huang, Bo Wang, Meredith Wright, Matthew R. Hoag, Allison Titong, Yue Liu
Format: Article
Language:English
Published: Nature Portfolio 2023-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-36942-3

Internet

https://doi.org/10.1038/s41598-023-36942-3

Similar Items